Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Down Syndrome (ds) Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

2 recruiting trials for Down Syndrome (ds). Eligibility criteria explained in plain English.

TrialFinderData lists 2 Down Syndrome (ds) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 3 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1), Woolfson Eye Institute (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). (drug, 1 trial), followed by Epi-ON corneal cross-linking (CXL).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
2
Total Trials
2
Recruiting Now
2
Phase 3 Trials
2
Sponsors

Frequently Asked Questions

There are currently 2 clinical trials for Down Syndrome (ds), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Down Syndrome (ds), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 2 Phase 3 trials for Down Syndrome (ds), representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.